SPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International) — SPLIS-OSPRI  

Sphingolipidoses Clinical Trial

Official title: Sphingosine Phosphate Lyase Insufficiency Syndrome - Observational Study and Patient Registry (International)

Status Recruiting

Clinical Trial Summary

This protocol aims to characterize the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS), also known as NPHS14, and to create a SPLIS patient registry. Medical records, radiological and pathology results, blood test results, and genetic information will be collected. Samples of blood, cheek cells, urine and stool may be collected for analysis. If a skin biopsy has been performed for medical care, cells from the biopsy may be analyzed. No treatment or other intervention is involved in this study. However, the effect of treatments administered by the patient's physician may be detected and monitored based on changes in the blood or urine.

Clinical Trial Description

This protocol aims to characterize the natural history and create a patient registry of sphingosine phosphate lyase insufficiency syndrome (SPLIS), a condition also known as NPHS14 or familial steroid-resistant nephrotic syndrome with adrenal insufficiency. SPLIS is a recently discovered genetic disease caused by recessive mutations in the SGPL1 gene. SPLIS can have effects on the kidney, adrenal gland, brain, skin, and blood cells. Some patients with SPLIS do not survive beyond infancy, whereas others live to adulthood. By monitoring the natural history of SPLIS over time in affected patients, the investigators will establish a clinical baseline that reflects how the disease progresses over time. This information may be useful in future clinical trials. The results may reveal which types of SGPL1 mutations correlate with best and worst patient outcomes. Some SPLIS patients are current on a regimen of high dose vitamin B6 supplementation on the advice of their treating physician. By including patients treated with B6, our study may provide evidence for the impact of B6 treatment on biochemical and blood markers of the disease. Our overall goals are to characterize the clinical, biochemical and metabolic manifestations of SPLIS and how these manifestations change over time within individuals with this condition. ;

Related Conditions & MeSH terms

• Sphingolipidoses

• NCT number: NCT04885179
• Study type: Observational [Patient Registry]
• Source: University of California, San Francisco
• Contact: Julie D Saba, MD, PhD
• Phone: 510-414-6317
• Email: Julie.Saba@ucsf.edu
• Status: Recruiting
• Start date: June 30, 2020
• Completion date: June 30, 2025